Patient Characteristics
| Patient | Age (y) | Sex | Cell type | Stage | Initial treatment | Further treatments | Survival (wk) |
|---|---|---|---|---|---|---|---|
| 1 | 69 | M | Large cell carcinoma | IIIB | Docetaxel + carboplatin | Docetaxel + carboplatin | 76 |
| 2 | 69 | M | Adenocarcinoma | IV | Docetaxel + carboplatin | Docetaxel + carboplatin | >87 |
| 3 | 70 | M | Adenocarcinoma | IV | Docetaxel + carboplatin | Docetaxel + carboplatin | >87 |
| 4 | 80 | M | Adenocarcinoma | IV | (Withdrew) | ||
| 5 | 69 | F | Adenocarcinoma | IV | Docetaxel + carboplatin | Gefitinib | 23 |
| 6 | 77 | M | Squamous cell carcinoma | IV | Docetaxel + carboplatin | Gemcitabine + carboplatin | 8 |
| 7 | 66 | F | Squamous cell carcinoma | IV | Docetaxel + carboplatin | Docetaxel + carboplatin | 19 |
| 8 | 54 | M | Squamous cell carcinoma | IV | Docetaxel + carboplatin | Gemcitabine + carboplatin | 30 |
| 9 | 78 | M | Squamous cell carcinoma | IV | Docetaxel + carboplatin | Docetaxel + carboplatin | 35 |
| 10 | 60 | F | Adenocarcinoma | IV | Docetaxel + carboplatin | Docetaxel + carboplatin | >44 |
| 11 | 79 | M | Squamous cell carcinoma | IV | Docetaxel + carboplatin | Docetaxel + carboplatin | 20 |
| 12 | 58 | M | Adenocarcinoma | IV | Docetaxel + carboplatin | Docetaxel + carboplatin | 25 |
| 13 | 69 | M | Poorly differentiated | IV | Docetaxel + carboplatin | Erlotinib | >41 |
| 14 | 50 | M | Adenocarcinoma | IV | Docetaxel + carboplatin | Gemcitabine + carboplatin | 15 |
| 15 | 60 | M | Squamous cell carcinoma | IIIB | Docetaxel + carboplatin | RT with docetaxel + carboplatin | 19 |
| 16 | 66 | M | Adenocarcinoma | IV | Docetaxel + carboplatin | Docetaxel + carboplatin | >11 |
RT = radiotherapy.